News from the Goldman Lab

20262025202320202019

New Platform Combines Precision Gene Targeting with Brain-Wide Delivery

Wednesday, July 8, 2026

A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain. The approach addresses two major challenges in neurological medicine—reaching therapeutic targets behind the blood-brain barrier and limiting unwanted effects elsewhere in the body—and could pave the way for new treatments for diseases including multiple sclerosis, Huntington's disease, and rare childhood white matter disorders.

The platform pairs specially engineered adeno-associated viruses (AAVs) with a delivery strategy that harnesses the brain's natural fluid transport pathways. Together, these innovations enabled researchers to deliver therapeutic genes broadly throughout the brain, preferentially targeting human glial cells while minimizing exposure to other cell types and organs.

“Gene delivery to the brain has always faced two major obstacles,” said Steve Goldman, MD, PhD, co-director of the University of Rochester Medicine Center for Translational Neuromedicine and lead author of the study, which appears in Nature Biotechnology. “You need a way to get therapies into the brain selectively and efficiently, and you need vectors that can deliver those therapies to the right cells once they get there. This work addresses both challenges simultaneously.”

From Dish to Brain: Researchers Chart Human Glial Cell Maturation

Thursday, May 28, 2026

A new study published in Nature Communications shows that human glial progenitor cells are a promising and safe cell product for transplantation. The research also defines the transcriptional and epigenetic signatures of these cells as they mature into astrocytes and oligodendrocytes, two essential support cell types in the brain.

“We believe that glia are particularly divergent compared to other species,” said lead study author John Mariani, PhD, a neuroscientist with University of Rochester Medicine and the first author of the new paper. “For this study, we grow these cells in vitro, and then we transplant them. We wanted to know what they look like before we transplant them and what they look like after. This sets the stage for long-term manipulation of these cells to engraft better, to respond better to the cues, and understand this process better, since it is an approach we are pursuing for cell therapies.”

This transplantation model may have implications for disorders such as multiple sclerosis, leukodystrophies, and Huntington’s disease, in which myelination, the insulating process that helps nerve cells communicate efficiently, is disrupted.